NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Regarding your statement

I believe NHS will try to stream line DCVAX-l approval process for all types of tumor cancers once they confirmed efficacy of DCVAX-l through rolling review of RWE with IFR means.

I believe NHS already streamlined DCVax-L approved access by placing it on the HHCD list.

What is likely happening here is that NHS has looked at all of DCVax-L's data and concluded that they need to get this treatment to its citizenry NOW. So, the NHS is using IFR funding to jump-start DCVax-L accessibility. It's as if NHS said to NICE, " DCVax-L is a godsend. We need to make this available now. I know you have to go through your process before our citizenry can have full access to DCVax-L but we are going to place DCVax-L on the HCD list to make this available NOW while you work through your process." Were you aware that NHS added significant additional funding to cancer treatment in 2024?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176178126